GPR65 recombinant proteins and antibodies

G protein-coupled receptor 65 (GPR65) is a receptor belonging to the G protein-coupled receptor (GPCR) family, primarily expressed in various immune cells, including T cells, B cells, and macrophages. GPR65 is considered a receptor related to intracellular pH changes, particularly functioning in acidic cellular environments. Studies have shown that GPR65 plays an essential role in regulating immune responses, inflammatory processes, and cell apoptosis. Its activation can modulate several downstream signaling pathways through G protein coupling, affecting the overall function of the immune system.

In recent years, GPR65 has gained significant attention as a potential target for immune modulation, especially for autoimmune diseases and cancer immunotherapy. GPR65 plays a critical role in regulating immune cell function, suppressing excessive immune responses, and maintaining immune balance. As such, it has emerged as a promising target for autoimmune diseases, inflammatory disorders, and cancer immunotherapy. Currently, drug development targeting GPR65 is still in its early stages. However, several biopharmaceutical companies are actively working on relevant drug development. For instance, some companies are developing GPR65 antagonists, aiming to suppress excessive immune responses by inhibiting GPR65 activity, which could be useful in treating autoimmune diseases such as rheumatoid arthritis. Additionally, GPR65 agonists are also being explored to enhance the immune system’s ability to recognize and attack tumors. In this way, GPR65 agonists could serve as an effective adjunct in cancer immunotherapy.

Biopharmaceutical companies such as Evotec and Moderna have made progress in GPR65 research, exploring its potential in immune therapies. Moreover, GPR65’s emerging role in cancer immunotherapy has attracted attention from more biopharma companies and research institutions. With continued research, it is expected that more innovative therapies targeting GPR65 will enter clinical development in the near future.

To assist in the development of GPR65-targeted drugs, DIMA BIOTECH can now provide full-length GPR65 recombinant membrane protein developed by its nanodisc membrane protein platform. GPR65 nanodisc is an optimal solution for screening small molecules targeting GPR65 with its natural structure. Furthermore, DIMA BIOTECH has also prepared a GPR65 single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.